{"name":"UCB BIOSCIENCES, Inc.","slug":"ucb-biosciences-inc","ticker":"","exchange":"","domain":"ucb.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lasosamide Oral Solution","genericName":"Lasosamide Oral Solution","slug":"lasosamide-oral-solution","indication":"Adjunctive treatment of partial-onset seizures in epilepsy","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"doxecitine and doxribtimine","genericName":"doxecitine and doxribtimine","slug":"doxecitine-and-doxribtimine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Lasosamide Oral Solution","genericName":"Lasosamide Oral Solution","slug":"lasosamide-oral-solution","phase":"phase_3","mechanism":"Lasosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.","indications":["Adjunctive treatment of partial-onset seizures in epilepsy"],"catalyst":""},{"name":"doxecitine and doxribtimine","genericName":"doxecitine and doxribtimine","slug":"doxecitine-and-doxribtimine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdVBkbGkwcVNaX1FhWDdNSFJBT05rOUZHanlVX0ctbXRqbU5RVXhQT1A1WUdGWlZwOWZoYjM1SnpUNS01SFZMRENTWlJlU2xhNzY3TmloaWhJeDZ0Ym1FYXJzb2Q0YmdXaTdKYUtmVENWVGhhTmtrb0VaZTZ1bzZLYlE1ekQtcmU1OS1sRFl4SHFjXzZwR3MxYUJQdm1FZWpOVHc?oc=5","date":"2026-03-25","type":"pipeline","source":"AJC.com","summary":"$2 billion biopharmaceutical facility coming to Gwinnett County - AJC.com","headline":"$2 billion biopharmaceutical facility coming to Gwinnett County","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOS0sweEFsOVlZdXJUMlFsUDhWN2dlWTRkdldUZHl6bG1fWXhnd0ptSDAwYVR1aFFpNk4wYndRM19Qanl5d2JlczdoMzNfZ1VEUXk4V1FORjNDa0xIU3JfeVd3bUxITkc4cWFMWTFGYXpncGluYU5fX3lIUTJvS0NXdzNzTThlSy0tUjhpV0l6MThoNEJyazZ4dzktZ0lUb25KVGpHOXJ5QlNzVHJVWVZnRWRNSVIyenp5TlBabzlKb0VKQQ?oc=5","date":"2026-03-24","type":"pipeline","source":"CBS News","summary":"Biopharmaceutical company UCB names Gwinnett County site of 1st U.S. biologics facility - CBS News","headline":"Biopharmaceutical company UCB names Gwinnett County site of 1st U.S. biologics facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUM3SDdEZHdFcHV1Y0pVckI2Y0RrVERCYVhEUS1lWUhNdUVObDY0VTFZbjEwM2R4dkt1a3hsTG50ck9ObnlMQXB5M2lkMm1yQ0pTSS12cnVWeG51V0tKU1JLbko2aXZ3M25UOFJGTkxUUWZ0RG0zb19hYmM1NHFucUZueE1POXJtb3QxSlczZmZzWC1LdDcyUHU2S3IyU29VSnJDWW9OZjJPdw?oc=5","date":"2026-03-12","type":"pipeline","source":"Medscape","summary":"Tachyphylaxis in Psoriasis: What’s Really Happening? - Medscape","headline":"Tachyphylaxis in Psoriasis: What’s Really Happening?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxOZU40eFRwSEYyT3ZneHhkT1lNeXI1cTBtNC1RMmQ2eWZ3aDlrSWZQMGRfSFZkUGtKQTJtUFpYaV9LaURWNWgzSHpWX01iTDRQTE9fWUVPeVBMaUNvOUthTDFwVWdHa2czZm9fM045Y3JNaWptcHhmTG03VW9Lak1iUGlpN21EUDBqNkd1emdvWmJaRWpkeW1yTnp3d3JPYU9wZkhVRTdyanA3R0FYQ1F3bFUtQjJlYTRqZEdqN05hNzV0aDRWQXhia2dPVjNyRFNhMWFrbW9PTWlRUmNjd3RINGVacnpNcUdPYTF1bUw3NG9mX0NJcGNBWDhFT2ctZTVkdHk2em9qblduT010QUhtSHRObFFfR0hOcXJ0Y0pDOUtTby1SSE5rVENtUmdHd0tTdGhpV3JwRDNsc1pzVkYwSi1aQk9nWGRIN3RxeU9R?oc=5","date":"2025-12-10","type":"deal","source":"BioSpace","summary":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights - BioS","headline":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Ex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNeWEyc0ZSQ29fczhyMHUxMG1ZUmk1YmM5bVdSOE1kOTFqQl9PRWZOV1FyMXJFdTZjSmNZdUwta3gySjJmN09xbkYydDhVQnRGU3E4RTJvb3Q1NnZSbzdLVmdoNTBhQUROT2hrbWRza3NFb2YzR1QtV3htZkFlbmNyWGM0anBEcXdzQ3NnZVpzdTVRX0FOenZJeDA1UVVWVTluai1yWS1QMWRWNExWTkxSMnBJZUdQUDE1Q1h1VGcyam1mdDlNbDJydTVTenUzZ1ZieWZkZGNKeVhJaXVway05RWxucnhjMkxMZFl4bkpleHhtaEJYQlhHXzhYcEt6LXpUVzVWLXdjUDFGbEl0UjBlenpORUp3Y3hqZFdUeFBzaW9XM2xnSV9IOG1VLXNQN3hZb1pPcEtfR0dZakZsRXFkeFBpdURTX3pDa1BXT1FpZjRmLXM?oc=5","date":"2025-09-17","type":"pipeline","source":"prnewswire.com","summary":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight - prnewswire.co","headline":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNeFZSeW8wNE9MbTBhZVMwQ1AyZU5YdTJDZEM2TFZOdnhNanQ2Z0VIcjNYenB3c0hQeXdhY0o0cl9NcjRTN1QyYWMzLUpwaXF4emp0Vnc3d0VmQ1lZRzRxN1BNbXR3blltYUNhYllza0duZzkyaERkYW90Q2kycENZMlZzcC01d2FfSVZ4OUVmeU9iaGVfbW1xdnlYVVowSXRiMEtqZ1pGbHNZaHBtcENhQnBoVnEwVVhGNFNNR0s2WWhfbm8?oc=5","date":"2025-08-25","type":"trial","source":"News-Medical","summary":"New study reveals long road to seizure control for people with focal epilepsy - News-Medical","headline":"New study reveals long road to seizure control for people with focal epilepsy - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNR2V1Q0tsZ1BIWHFZX3phMjZMNGhVeUJaaWREdC0xcHd4VWhjTVFnUl9qVTY2dk1Ia2NZMmx1MVJTZGlFMW9MNGstQWR3TmdfUnVzM2ZaTWhPR1M5MVlza1l6SU90ejJZX3Znc29rRU5BVUdBQ0dDdGtUOXVFaUlBN3FhN2Q3SmQz?oc=5","date":"2025-08-12","type":"pipeline","source":"Yahoo Finance","summary":"United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK - Yahoo Finance","headline":"United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPWmdydm41akl6Y3VGd1NUSlFObGxQOU93MEswRWpUdEFjNFpUWkRFZnhVTXNwcG9nWTBtZFB5ak5RMjlaVi1NUFR6TzZHRkJlZmwwa1FxMHVQRzVlQ0tzdzNaTThfRkhmZFZISWxGRjZiNWxYbGQ3aDRNbkZnNThhTzc0dGtPaFRIR29tR1hpMUFwZkJMQWJHOS1WdWJzS3FWdFBlSWVR?oc=5","date":"2025-06-14","type":"pipeline","source":"Global Atlanta","summary":"Belgian Pharma Giant With Atlanta Base to Invest Billions in U.S. Factory - Global Atlanta","headline":"Belgian Pharma Giant With Atlanta Base to Invest Billions in U.S. Factory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTzhQQzVidkFuNE5fRDlXMlVEQi1Ha3ZyeGV5Y2FGNjFtd3A3RzZHNzh5VVMzazU3T1BWTmpRS2E4aFMtMVNHUWFKWDZfTTljWENxdnRXaVVia0FqLUpOSjBUR3I3VHhuZ3FnLW1oVnFXVnd4Sjg3QTZDc1FLR1puVDVlWVRmT1dxRjFKOGhVU2dCNU43MTFhaQ?oc=5","date":"2025-06-13","type":"pipeline","source":"Manufacturing Dive","summary":"UCB to open $5B US factory - Manufacturing Dive","headline":"UCB to open $5B US factory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPbHE0Mm9YMGxVUkZ3dDZDNDA1Wnl1VndPOTBZSWNhQ19zbE1NMjA5TDJnc3pEdHR1Mnd5WU5UV1JlSEFQVWI2a1EwNVVjNmx6MV9yajVaZjRqbHRFdEtLdndHVEM4dVVvTEpaaVFlYjF6cHhzLXBvcVdCMDlyMGZqRjFMZ3k3Vk9DbWNDV2tiRU9kN3hjLS14Qk9vaU1pay1vX0ROZmlkenZ6akgwM3hMTzFHcGEtYldmSHVIQmpvME50NjctWFpv?oc=5","date":"2025-06-12","type":"pipeline","source":"UCB","summary":"UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity - UCB","headline":"UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}